Compare Natera Inc. Common Stock (NTRA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs VF Corp — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while VF Corp trades at $16.38 (market cap $6.32B). The key difference: Natera Inc. Common Stock is far larger — about 9× VF Corp's market cap, and VF Corp pays a 2.24% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and VF Corp for 64 Days on average.
| NTRA | VFC | |
|---|---|---|
Market Cap | $57.03B | $6.32B |
Volume | 1,131,157 | 14,983,623 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $21.55 |
52-Week Low | $179.42 | $12.62 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $56.18B | $10.60B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VFC trades at $16.48, up 4.37% today, with a bullish technical signal and a consensus analyst price target of $18.33. Recent earnings show mixed results, with a Q4 2025 beat but Q1 and Q2 2026 misses. Revenue declined to $9.5B in 2025, with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a strong gross margin of 54.97% but faces challenges from high debt and weak performance in its Vans brand.
The outlook is cautiously optimistic, supported by valuation discounts (P/S 0.67) and growth in outdoor brands, but execution risk on the Vans turnaround and high leverage pose significant threats. Near-term price action is buoyed by technical momentum, yet fundamental recovery hinges on sustained revenue improvement and debt reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
